GRM1 regulates the calcium levels of the postsynaptic cytosol as a G protein-coupled neurotransmitter receptor, whose mutations mainly result in schizophrenia and bipolar disorder [15], and has been regarded as a potential novel drug target for refractory epilepsy therapy [16]. Here, GRM1 is linked to epilepsy.